Effectiveness of Subcutaneously Administered Leuprolide Acetate to Achieve Low Nadir Testosterone in Prostate Cancer Patients

Reviews in Urology

Christopher M. Pieczonka¹  Joseph Renzulli²  II³  Przemyslaw Twardowski⁴  Jason Hafron⁵  Deborah M. Boldt-Houle⁶ 

[1] Associated Medical Professionals, Syracuse, NY;Brown University, Providence, RI;Michigan Institute of Urology, Troy, MI;Providence Hospital Santa Monica, Santa Monica, CA;Tolmar Pharmaceuticals Inc., Lincolnshire, IL;University of Chicago, Chicago, IL

关键词: Prostate cancer;    Leuprolide acetate;    Nadir testosterone;    Androgen deprivation therapy;    LHRH agonist;   

DOI  :  10.3909/riu0798

学科分类：基础医学

来源: MedReviews, LLC

【 摘 要 】

Evidence suggests lower nadir testosterone levels during the first year of androgen deprivation therapy improve advanced prostate cancer clinical outcomes. We evaluated pivotal trials for subcutaneously administered leuprolide acetate (1-, 3-, 4-, and 6-month doses) to determine nadir testosterone levels. Pooled analysis showed 99%, 97%, and 91% of patients reached nadir testosterone ≤20, ≤10, and ≤5 ng/dL respectively (median ≤3 ng/dL). Across all available categories, $88% of patients reached nadir testosterone ≤5 ng/dL, and <3% experienced a microsurge. Achievement and maintenance of low nadir testosterone levels may improve progression-free survival and time to onset of castrate-resistant prostate cancer.

【 授权许可】

Unknown